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Abstract
Radiation therapy for lung cancer and cancers of the upper thorax is limited by
side effects to normal tissue of the lung. An understanding of mechanisms leading to
radiation induced lung damage is essential to developing protective agents. In this thesis
an anti-oxidant and anti-inflammatory agent Genistein was investigated for its potential
to affect DNA damage, tissue inflammation, functional deficits and survival. We
hypothesized that chronic oxidative stress and the subsequent inflammatory response play
a key role in the development of major lung complications, radiation pneumonitis and
fibrosis. If side effects of radiation could be reduced, then larger doses could be
delivered to the tumor with a better chance of eradicating the disease.
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Chapter 1: Introduction

1

1.1 Normal lung response to radiation
There were an estimated 159,900 new cases of cancer in Canada in 2007 [1] and
at least half of all patients will undergo radiation therapy as part of their cancer treatment
[2]. Lung cancer is the most common cancer, with 23,300 new cases in Canada in 2007
and has one of the lowest five year survival ratios of 16% resulting in 19,900 deaths in
2007 [1]. The lung is a relatively radiosensitive organ [3] and normal tissue toxicity is a
dose limiting factor for radiotherapy of tumors in the upper thorax such as lung cancer,
breast cancer, thymoma and lymphoma [4]. The main side effects of radiotherapy in the
lung are pneumonitis and fibrosis, characterized by symptoms of congestion, cough,
shortness of breath, chest pain, and reduced diffusion capacity/volume. Five to twenty
percent of patients will develop severe pulmonary side effects from radiation treatment
[4]. These effects reduce the functional capacity of the lung and may even lead to death.
The severity of radiation pneumonitis and fibrosis depends upon the dose, fractionation
schedule, volume and region irradiated [5]. Currently there is little that can be done in
terms of prevention and thus there is a need for effective measures to mitigate and treat
damage associated with exposure to ionizing radiation. The ability to prevent radiationinduced toxicity without affecting antitumour efficacy has the potential to enhance the
therapeutic benefit for cancer patients while decreasing their risk of serious adverse
effects. Reducing or preventing the development of radiation-induced functional deficits
would allow for dose escalation which in turn would lead to better chances of tumor
eradication and for potentially better patient quality of life following radiotherapy. The
exact mechanisms of radiation-induced damage are complex; however, an agent capable
of mitigating these effects would be highly beneficial to treatment strategy.
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1.2 Direct and Indirect Effects of Radiation
DNA is considered the critical target in the irradiation of biological tissue.
Radiation may interact directly with the critical target where an atom of the DNA is
ionized or excited that initiates a chain of events leading to biological effects. Radiation
may also interact indirectly by interacting with other molecules or atoms in the cell to
produce free radicals that may then diffuse within the cell to reach and damage critical
targets [5]. Water is a likely target of the indirect action since the cell is composed of
about 80% water. In this case a photon interacts with the water molecule to produce an
ion radical and a secondary electron. The ion radical is highly reactive but has an
extremely short half life and decays to form a free radical. The ion radical reacts with
another water molecule to form a hydronium ion and a hydroxyl free radical. The
hydroxyl radical can then diffuse within the cell to react with the critical target DNA. It
is this indirect action of ionizing radiation that may be modified by means of radical
scavengers to reduce the biological effect of radiation. This is an important area of
research to reduce the side effects of radiation therapy.

1.3 Pulmonary Response to Radiation Therapy
The lung response to radiation is a complex and dynamic response with many
interactions at the cellular and molecular levels. The response to radiation involves many
cell types including macrophages, epithelial pneumocytes, endothelial cells, and
fibroblasts [6]. Damage to these cells and corresponding normal tissue from radiation
involves cell death, production of reactive oxygen species, alterations in gene expression,
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and the production of cytokines [7].

This multicellular reaction is modulated by the

production of specific cytokines and growth factors [8, 9]. A simplified schematic of the
cellular interactions due to growth and inhibitory factors is shown in Figure 1-1.
The alveolar epithelium consists of type I and II epithelial cells. Type I cells are flat
epithelial cells that cover 90% of the alveolar surface. Type II cells replicate and mature
to produce type I cells, and also produce surfactant [10]. Following radiation, type I cells
are damaged and lost from the alveolar surface and type II cells rapidly proliferate to reepithelialize the alveolar surface. Type II cells may also be injured by radiation and this
triggers a release of surfactant [11, 12]. A large number of cytokines, growth factors and
cytokines regulate this response [13]. Alveolar macrophages are a major source of
cytokine signalling driving the inflammatory process following irradiation.

Cellular

injury of the macrophage causes altered gene expression and a subsequent release of
cytokines such as tumor necrosis factor α (TNF-α) and transforming growth factor β
(TGF-β). In the target cell, the fibroblast, cytokine receptors are activated and signal
transduction occurs stimulating collagen genes [8, 14]. The cytokine cascade is persistent
during the months following radiation and results in a chronic inflammatory state during
the time leading up to and during the expression of functional damage [14, 15]. In
addition to being a source of inflammatory cytokines, macrophages are also a large
source of reactive oxygen species (ROS) generated in response to the inflammatory
signals following radiation [16]. Radiation causes an initial burst of ROS production due
to the ionization of water molecules, but the activation of inflammatory cells and
induction of inflammatory cytokines causes persistent changes in cell signalling and
continued production of ROS at late times (Figure 1-2). The normal tissue response

4

Figure 1-1: Possible cellular communication following irradiation. The lung response is a complex and
dynamic interaction between many different lung cell types. Cytokines play a key role in signalling
between cells. From [9]
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including the propagation of ROS and oxidative stress is an active process that leads to
the development of clinically evident early and late lung damage [13, 14].

1.4 Acute and Late effects in Lung
Radiation-induced lung injury has classically been separated into two phases:
radiation pneumonitis and radiation fibrosis. Following radiation there is a latent period
before clinical symptoms arise. However, during this time there are changes at the cell
and molecular level leading to the development of pneumonitis and fibrosis. Changes in
cytokine expression have been detected as early as one hour following radiation [15].
Acute radiation pneumonitis usually occurs between 1-6 months following irradiation
with symptoms of cough, dyspnea, chest pain and occasional fever.

Radiographic

changes are variable and may reveal local infiltrate within the radiation field or diffuse
infiltrate outside the radiation field [16]. Histopathology following irradiation shows a
loss of type I pneumocytes and endothelial cells, release of surfactant and fibrin in
alveoli, a decrease in macrophages, and interstitial oedema.

During radiation

pneumonitis there is tissue inflammation with an increase in type II pneumocytes,
leukocytes, fibroblasts, alveolar macrophages and oedema [17].
Radiation pneumonitis may resolve after a few weeks and can also be followed by
chronic inflammation and fibrosis that usually develops by 6 months but can continue to
progress for 1-2 years following irradiation.

Radiation fibrosis is characterized by

vascular damage and collagen deposition [18]. Fibrotic changes in the lung are a result of
interactions between many cell types involving the production of inflammatory and
fibrotic cytokines by cells such as macrophages and fibroblasts [6].
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Radiation
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ICAM, VCAM, E-selectin

↓

 Inflammatory cells
neutrophils, macrophages, monocytes
Pro-inflammatory cytokines
TNF-α
IL-1β
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DNA damage
Figure 1-2: Possible cycle of inflammatory mediators post irradiation. Radiation causes an increase in
cellular adhesion molecules, allowing for increased extravasation and arrest of inflammatory cells in lung
tissue. Inflammatory cells secrete pro- and anti-inflammatory cytokines, and the balance is regulated by
NF-κB. Inflammatory cells such as monocytes and activated macrophages produce high levels of ROS that
can lead to DNA damage.
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Radiographic evidence of scarring associated with fibrosis can be seen within the
irradiated field. Symptoms related to radiographic changes and fibrosis depend upon the
extent of lung parenchyma involved and the pre-existing pulmonary reserves [18]. If the
lung volume irradiated is small, the patient may not exhibit symptoms. For larger
irradiated volumes there may be symptoms of cough, progressive chronic dyspnea, and
chest pain due to reduced diffusion capacity similar to those observed during pneumonitis
[19]. Histopathology during fibrosis shows loss of capillaries, thickening of alveolar
septa, and narrowing of alveoli [17]. The defining feature of fibrosis is the increasing
rigidity of tissue due to increased collagen deposition stimulated by pro-fibrotic cytokines
such as TGF-β [10, 20]. Increased expression of pro-inflammatory and pro-fibrotic
cytokines play a key role in the development of fibrosis. Inflammation is initiated as a
mechanism to protect and repair damage to normal tissue from radiation. When the
balance between pro- and anti-inflammatory processes becomes disturbed, a state of
chronic inflammation can result in further damage to tissue. Both pneumonitis and
fibrosis can severely impact upon the quality of life for patients. There is a need to better
understand the mechanisms contributing to the development of normal tissue damage and
clinical symptoms as well as effective measures to prevent and mitigate radiation
induced-lung injury.

1.5 Lung Architecture
The lung has a large diffusion area for gas exchange created by a series of
branching airways. The trachea branches into two main bronchi that enter each lung,
which branch into lobar and segmental bronchi down to terminal bronchioles. Terminal
bronchioles divide into respiratory bronchioles with occasional alveoli and then into
8

alveolar ducts fully lined with alveoli [18]. The portion distal to the terminal bronchiole
is the region where gas exchange occurs and forms a functional subunit (FSU) called the
pulmonary lobule or acinis. The FSUs in the lung are arranged in parallel and many
bronchi and acinis work together [5]. Normal tissue tolerance is the dose required to
produce a functional deficit, and depends upon the number and radiosensitivity of the
target cells in the FSU, the functional reserve of the organ and structural organisation of
the FSU [21].

If small volumes of lung are irradiated, the remaining FSU can still

perform their function. The parallel arrangements of the FSU in the lung give rise to a
graded dose response [22]. However, the lung becomes dose limiting when large volumes
of lung are irradiated and there is not sufficient reserve capacity in the remaining FSU [5,
23]. Furthermore, low doses to large lung volumes are more damaging than the same
mean lung dose to small lung volumes(eg. 9-12 Gy to 100% of lung volume produces
more functional lung damage than 27-36 Gy to 25% of lung volume) [24, 25]. Clinically
it is recommended that no more that 30-35% of the lung receive a dose larger than 20 Gy
(V20 parameter), and that the mean lung dose is less than 20-23 Gy [26].

1.6 Volume and Regional Effects
In addition to dose and volume the lung response is dependent upon the location
of the irradiated sub volume within the organ [7, 23, 27-30]. Several studies have shown
the base of the lung to be more sensitive than the apex. Using either breathing rate or
lethality for the endpoint, studies in mouse lung by Travis, Liao and Tucker [23, 29, 30]
investigated the relationship between dose, volume and region of irradiated lung on the
probability of radiation induced complications. Irradiation of a smaller volume in the
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base of the lung than in the apex was required to achieve a given effect ED50 for
breathing rate or LD50 for lethality (Figure 1-3). The ED50 is the effective dose required
to produce a functional effect in 50% of subjects. The LD50, is the dose lethal to 50% of
subjects. Clinically it has also been reported that patients who undergo irradiation of
tumours in the lower lung are at increased risk of developing pneumonitis than those with
tumours in the upper lobe [31-33]. The difference in regional sensitivity is not fully
understood but is presumed to be due to differences in the number and location of FSUs
as there are more FSUs in the base of the lung than the apex [30].
Inclusion of the heart within the irradiation field has also been reported to increase lung
damage[34, 35] but this effect was not confirmed in other studies [25, 33].
Previous studies in our lab have used a rat model to demonstrate the regional
sensitivity of the lung to radiation [27, 28]. Radiation-induced lung damage was assessed
in fibroblasts using a cytokinesis block micronucleus assay to evaluate DNA damage.
Following whole lung irradiation there was a large increase in micronuclei formation
compared to unirradiated controls.

Following lower lung irradiation, there were

comparable levels of DNA damage within the irradiation field to that observed during a
whole lung irradiation and also a high amount of damage in the shielded upper lung.
When the apex of the lung was irradiated, the in-field damage was approximately half
that seen during whole lung irradiation and in the out-of-field lower lung there was only a
slight increase in damage seen above background levels (Figure 1-4).
The level of damage in the upper irradiated lung was similar to the out-of-field
damage in the upper lung when the lower lung was irradiated. These findings suggest
that irradiation of the base of the lung produces larger amounts of damage in-field and
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Figure 1-3: Breathing rate and lethality as a function of partial volume irradiated. The base of the lung is
more sensitive than the apex. From [30]
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out-of-field than irradiation of the apex. The administration of radical scavengers Mn
superoxide dismutase (MnSOD) or CuZnSOD or nitro-L-arginine methyl ester (L NAME) 30 minutes prior to irradiation was effective in reducing the damage in field by
10-30% and 50-60% out of field.

This suggests that damage created in field may

generate signals to produce superoxide radicals, and inflammatory cytokines that are
transported by diffusion or blood circulation to cause damage in the whole organ
including out-of-field regions.

Following irradiation there is an induction of an

inflammatory response meant to protect and aid in repair of damage. However, this in
turn causes the production of additional reactive oxygen species (ROS) that can also
cause DNA damage. Increases in inflammatory cytokines interleukin 1β (IL-1β) and
transforming growth factor-β1 (TGF-β1) were measured in the plasma following
irradiation. The anti-oxidant agents were more effective in protecting against indirect
damage caused by tissue reactions (inflammation) than the direct action of the radiation
itself. The more radiosensitive lower lung was able to generate a greater inflammatory
response than the upper lung. An analysis of these data in combination with mouse
functional data from Travis et al. [23, 29, 30] proposed a model that incorporated in-field
and out-of-field effects to better predict lung response [36]. The model predicted that for
a given proportion of target cells, greater damage would be expected when the base of the
lung was irradiated. Thus, when predicting the likelihood of complications arising from
standard dose and volume data, one must also consider the additional impact of where the
irradiated sub-volume is located within the lungs and out-of-field effects.
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Figure 1-4: Micronuclei Formation in lung fibroblasts following whole and partial lung irradiation.
Irradiation of the whole lung shows high levels of damage in and out-of-field. When only the lung base
was irradiated, there were similar levels of damage in-field compared to the whole lung irradiation, and a
large amount of damage also seen in the upper unirradiated lung out-of-field. When the apex of the lung
was irradiated, there was lower damage seen in-field than when the whole lung was irradiated, and there
was very little additional damage seen out-of-field in the lower lung. Data from [28]
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1.7 Fractionation
Radiation is sometimes delivered as a single dose, but it is more often administered in
a series of fractions. Dividing a radiation dose into fractions spares normal tissues
because it allows for repair of sublethal damage and repopulation between treatments.
Fractionation increases tumor damage over multiple doses due to reoxygenation of the
tumor as hypoxic cells are more radioresistant than well oxygenated cells. It also allows
reassortment of cells through out the cell cycle (cells are most resistant during S phase,
and most sensitive during M and G2) making them more sensitive to subsequent radiation
doses [5, 37]. A balance is achieved to minimize damage to normal tissues while
maximizing damage to tumor tissue. Each fraction progressively adds to the tumor cell
kill.
Cell survival (S) following radiation is often described by the linear quadratic (LQ)
model

S D =+
` a

@ αD + βD
b

2

c

n

(Equation 1)

where D is the dose, and α is the constant describing the initial linear slope of the survival
curve, β is the constant describing the quadratic component of cell kill, and n is the
number of fractions[38]. This assumes that there is complete repair of sublethal damage,
and that each fraction has equal effect. With respect to damage to normal lung tissue, this
model was extended to the linear quadratic with time (LQT) to take proliferation of lung
cells between fractions into account

S D =+
` a

@ αD + βD
b

2

c

n + γT

(Equation 2)
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where γ is the overall time dependence and T is the overall treatment time[38]. The
effect of a treatment fraction does not depend upon the time (its position) within the
treatment in which it is given[39]. To compare two fractionation regimes an isoeffective
dose formula of functional damage is used
D b

E = α 1 + εT + ηT

2

c

2

E

D + βD n

(Equation 3)

where ε and η modify the effect of α/β over time, parameters derived from modeling of
clinical data are α/β = 4.1Gy, ε = -0.025/day, and η = 28x10-5 /day-2 [40].
Clinically, fractionated treatment delivers smaller therapeutic doses of radiation
daily, usually less that 2Gy. Palliative treatments may deliver fewer doses in larger
fractions (ie 5 fractions of 4Gy, or a single 10Gy dose). Many studies have examined the
effect of treatment schedules on the development of radiation pneumonitis and fibrosis
[41-43].

The studies focused on single versus fractionated and hyperfractionated

radiation treatments. It was shown that a single dose of 15Gy of

60

Co gamma rays

produced greater histological damage than 10 daily fractions of 3Gy, or 30 fractions of
1Gy three times per day to the same volume. Fractionation reduced the percent of lung
parenchyma involved in pneumonitis from 70-80%, to 40-50% and 30-50% respectively.
There was no difference in fibrosis at later times depending upon treatment [42].
Radiation pneumonitis and fibrosis may be independent damage events but recent data
suggest that a cyclic inflammatory response and chronic inflammation is responsible for
the development for the spectrum of radiation induced lung damage from pneumonitis to
fibrosis [44, 45].
However, new advancements in treatment planning using stereotactic body radiation
therapy (SBRT) allows for increased precision in tumor targeting and this has revived the
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use of hypofractionation [46]. The large dose per fraction assumes that tumor and
surrounding healthy tissue would be eradicated (i.e. ablated as during surgery), volumes
of normal tissue obliterated are small, volumes beyond the tumor that receive a lower
dose are below the threshold dose and will recover, and that there is sufficient reserve
capacity in the organ to maintain organ function. For example, at Princess Margaret
Hospital in Toronto they are investigating the use of 3 fractions of 15-20Gy to small
lesions to examine if it results in better local control while maintaining reasonable levels
of side effects.

The use of agents capable of protecting against side effects would be

highly beneficial to this treatment strategy as well.

1.8 Universal Reaction - Acute Respiratory Distress Syndrome (ARDS)
The lung response to radiation is similar to that of its response to other types of
injury such as lipopolysaccharide(LPS), bleomycin, endotoxins, many chemotherapeutics
and hyperoxia [7, 8, 47]. The similar lung inflammatory response to various damaging
agents suggests that the aspects of normal tissue response are universal and independent
of the damaging agent [7].
Mechanisms associated with radiation-induced lung damage may be better
understood by examining the universal lung response to various damaging agents.
Bleomycin is a chemotherapeutic agent that causes an inflammatory lung response
similar to that of radiation.

Superoxide dismutase (SOD) is part of normal cellular

defence against oxidative damage that leads to pulmonary fibrosis. When mice knocked
out for extracellular SOD were treated with bleomycin there was a marked increase in
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inflammation, hydroxyproline content and interstitial fibrosis at 14 days post treatment
[48].
Direct lung injury (pulmonary infection, aspiration, or toxic inhalation) or indirect
lung injury (sepsis, shock, or trauma) results in an inflammatory response called acute
respiratory distress syndrome (ARDS).

ARDS is a condition of inflammation and

increased vascular permeability in response to pulmonary parenchymal injury and ends
with tissue repair and fibrosis [49]. Symptoms in ARDS patients are similar to those with
radiation induced lung damage such as dyspnea, decreased lung compliance, and diffuse
alveolar infiltrates on chest radiographs [50]. These clinical symptoms are evident within
days of lung injury [49, 50] whereas radiation induced lung damage is not apparent until
months following radiation. It is understood that cellular and molecular changes are
occurring during this apparent latent period.
ARDS is characterized by three phases of cellular changes in the lung: acute
exudative phase, proliferative phase, and a fibrotic phase [49-51]. The first exudative
phase is characterized by the activation and infiltration of inflammatory cells and occurs
24-48 hours following lung injury [50]. There is widespread necrosis of type I alveolar
cells and infiltration of neutrophils from the capillaries into the pulmonary interstitium
and air space [49]. Plasma proteins and fibrin accumulate on the denuded basement
membranes forming hyaline membranes [51]. The proliferative phase is initiated within
3-10 days characterized by infiltration of the interstitium with fibroblasts and continued
exuberant infiltration with inflammatory cells [52]. Type II pneumocytes proliferate and
replace type I pneumocytes on the basement membrane. Fibroblasts begin to deposit
collagen thickening the alveolar walls at the site of inflammation.

Macrophages
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phagocytose the hyaline membranes and other cellular debris [51]. The fibrotic phase
results in consolidation and fibrosis of the pulmonary parenchyma 7-14 days following
lung injury [49, 51, 52].
Activation of NF-κB is a signature event of ARDS. NF-κB is a transcription
factor for a variety of factors that are directly or indirectly involved in the development of
ARDS including pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-α), chemokines,
colony-stimulating factors, and interferons [52]. A positive feedback loop exists as NFκB can be activated by IL-1 and TNF-α to further amplify the signal [53]. Negative
feedback of NF-κB occurs at the extracellular level where IL-1 and TNF-α also cause
production of the regulatory anti-inflammatory cytokine IL-10 to attenuate the signal
[54].

High binding activity of NF-κB and concentration of inflammatory mediators has

been shown in bronchoalveolar lavage fluid (BALF) of ARDS patients. The level of NFκB binding activity correlates with the degree of respiratory dysfunction [55].
Inflammatory mediators play a key role in the pathogenesis of ARDS. Proinflammatory cytokines tumour necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β)
are derived from activated macrophages and are found in BALF during the exudative
phase [50, 55-57]. The ratios of cytokine concentrations in BALF fluid compared to
serum levels suggest a pulmonary origin [56, 58, 59]. Both TNF-α and IL-1β act via
specific cell membrane-bound receptors and activate neutrophils and induce an upregulation of adhesion molecules [50]. A similar response occurs in animal models
following LPS exposure. TNF-α and IL-1β are released and in turn activate a second
level of inflammatory cytokines, lipid mediators, reactive oxygen species, and upregulate
cellular adhesion molecules resulting in inflammatory cell recruitment [50]. The plasma
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levels of TNF-α and IL-1β peak within hours of the insult leaving a narrow window for
therapeutic intervention [49]. Additional inflammatory cytokines IL-6 and IL-8 have
been shown to be elevated in ARDS patients [49-51, 55, 60]. IL-6 plays a role in the
acute exudative phase of ARDS and is also raised in other acute conditions such as burn,
surgery and sepsis.

IL-8 is a main chemotactic factor for neutrophils [61].

The

concentrations of these cytokines correlate with the severity of ARDS disease, and high
levels are indicative of a poor prognosis [52].
A state of chronic inflammation can result from the self-propagating ability of
many cytokines which can lead to the development of tissue damage in ARDS. The
balance between pro and anti-inflammatory cytokines is a critical mechanism to limit the
biological response. IL-10 is an anti-inflammatory cytokine that inhibits the release of
pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) from macrophages and monocytes thus
regulating the balance between pro-inflammatory versus anti-inflammatory response
[62]. Lower levels of IL-10 in plasma and BALF of patients correlated with ARDS
development [63]. Administration of anti-inflammatory IL-10 showed protective effects
in animal models of ARDS and higher levels of IL-10 correlate with better clinical
outcome in patients [50]. A study of the balance of pro and anti-inflammatory cytokines
showed specific temporal patterns of expression with anti-inflammatory cytokines
peaking at early times (1-3 days) and pro-inflammatory cytokines rising during the course
of study up to 3 weeks [56]. This supports the idea that the biological changes in ARDS
are dependent upon the net cytokine balance and these patterns are critical to disease
progression.
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1.9 Lung Inflammation Post Irradiation (PI) – Cell Adhesion Molecules
Cell adhesion molecules (CAMs) are expressed on the surface of endothelial cells
and play an important role in inflammation in the lung following irradiation by aiding in
leukocyte migration from the microvasculature into the surrounding lung tissue [64].
Radiation also directly induces expression of intercellular adhesion molecule-1 (ICAM-1)
and E-selectin on endothelial cells within a few hours following irradiation [65, 66].
Following adhesion of leukocytes, such as neutrophils, to the vascular endothelium,
inflammatory cells extravasate and migrate into the injured lung tissue. Inflammatory
cells cause an upregulation of proinflammatory cytokines, such as TNF-α and IL-1, that
can also stimulate induction of a wider variety of CAMs including E-selectin, P-selectin,
ICAM-1, and vascular cell adhesion molecule-1 (VCAM-1). ICAM expression has been
found to be elevated in BAL of patients who develop pneumonitis compared to those who
do not [67]. Similar results were also seen in a rat model [68]. Mice knocked out for
ICAM-1 gene expression show a reduced inflammatory response, and less infiltration of
inflammatory cells into the lung tissue [47, 69]. Together these results emphasize the
importance of CAMs immediately following irradiation in recruiting inflammatory cells
into lung tissue causing inflammation.

1.10

Lung Inflammation Post Irradiation (PI) – Inflammatory Cytokines
The progression of inflammation in the lung following irradiation is similar to the

inflammatory process observed in ARDS. Several studies have investigated the changes
in inflammatory cells and mediators in lung tissue following irradiation such as
transcription factors, cytokines, and cell adhesion molecules [10, 11, 44, 70-76]. Several
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of these studies have shown that there is a cyclic pattern of cytokine upregulation
following irradiation and that the temporal patterns of expression are critical in the
development of radiation pneumonitis and fibrosis [8-11, 15, 44, 71-73, 77].
Several studies have also investigated the genetic component of susceptibility to
radiation-induced lung damage to elucidate further the association between inflammation
and tissue response [78-86]. Travis [87] compared quantitative measurements of lung
fibrosis to the survival at 2Gy of skin and lung fibroblasts from C3H fibrosis resistant
mice and C57BL/6 fibrosis prone mice. Data showed differences in the severity of
radiation-induced lung fibrosis; however, the radiosensitivity of the fibroblasts did not
correlate with the differences seen in radiation response between the fibrosis prone and
resistant mice.

This provides support for the idea that factors other than intrinsic

radiosensitivity must exist to account for the differences in fibrosis response. It is
currently thought that a cyclic expression of pro-inflammatory cytokines is a major
contributing factor to the development of radiation-induced lung damage.
Initially it was thought that there was a latent period between the time of
irradiation and when symptoms manifested clinically [10, 88]. However, more recently it
has been shown that cytokine signalling and changes in gene expression can be seen
within hours of irradiation [15]. Rubin et al. [10] demonstrated early changes in cytokine
production underlie the pulmonary radiation response. Radiation fibrosis prone C57/BL6
mice were irradiated with 12.5Gy and their lungs examined at various times post
irradiation (PI). RNA expression of inflammatory cytokines IL-1α, IL-1β, and for profibrotic cytokines TGF-β and platelet derived growth factor (PDGF) was assessed.
Interleukins (IL’s) are strong stimulators of inflammatory cells, particularly lymphocytes
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and macrophages. IL-1α in particular showed significant increases from 2 to 8 weeks
post irradiation (PI) and remained elevated with a second peak at 26 weeks PI. These
data suggested that a pro-inflammatory stimulus plays a role in the onset and
maintenance of the pneumonitis phase from 8 to 16 weeks PI, and then persists into the
later fibrotic phase. TGF-β and PDGF are cytokines that stimulate extracellular matrix
remodelling leading to the development of fibrosis. TGF-β and PDGF showed marginal
increases in expression above background levels, increasing at later times where they
play a larger role in fibrosis. The results of this study provide evidence for the hypothesis
that cellular communication between pulmonary and inflammatory cells occurs very early
following irradiation and that it continues to contribute to the development of
pneumonitis and fibrosis.
Rube et al. [72] demonstrated a significant radiation-induced increase in TNF-α in
lung tissue during pneumonitis. TNF-α is a pro-inflammatory cytokine that plays a role
in radiation pneumonitis by inducing expression of adhesion molecules that recruit
leukocytes to the sites of tissue damage, and in fibrosis by stimulating growth of
fibroblasts and collagen deposition. C57/BL6 mice were irradiated with 12Gy and their
lungs were analysed during the latent and pneumonic phases.

Within 1 hour of

irradiation mRNA levels and protein levels of TNF-α were elevated and correlated with
increases in inflammatory cells, particularly macrophages, into the lung parenchyma.
TNF-α was also elevated at later times from 2 to 24 weeks PI reaching a peak at 8 weeks
PI at the onset of pneumonitis. These data suggest that TNF-α plays a critical role in the
time immediately following irradiation and leading up to the development of symptoms.
An additional study [44] further investigated the time course of the pro-inflammatory
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cytokine upregulation following irradiation. Early increases in TNF-α were seen at 1
hour PI, and in IL-1α and IL-6 at 6 hours PI and then returned to basal levels for up to 2
weeks PI. During the pneumonitis phase TNF-α, IL-1α, and IL-6 were again all elevated
and reached a peak at 8 weeks PI. This further confirmed the temporal pattern of proinflammatory cytokine expression leading up to the development of histological
discernable pneumonitis.

A further study showed the bronchiolar epithelium as a

prominent source of these inflammatory cytokines [74].
Hong et al. [11] found similar time dependent increases in TNF-α gene expression
following radiation of C57/BL6 (fibrosis prone) and C3H/HeJ (fibrosis resistant) mice.
Following a 20Gy irradiation there was upregulation of TNF-α, and IL-1α and IL-1β at 1
hour PI that persisted for 16 hours and subsided by 24 hours PI in the C57/BL6 mice.
The C3H/HeJ mice showed a similar response, and IL-1β showed the greatest increases
in expression within the first hour, peaked at 8 hours and subsided by 16 hours PI. These
data again support a rapid induction of cytokine response following irradiation. It also
shows differences in cytokine response between strains that may account for differences
seen in the development of pneumonitis and fibrosis.
TGF-β is another important cytokine that plays a role in the radiation response in
lung [73, 89-92].

TGF-β is widely expressed in normal and tumor tissue [92].

Following irradiation TGF-β is produced locally in addition to circulating TGF-β which
may be activated by ROS. TGF-β acts as a chemoattractant for fibroblasts, macrophages
and monocytes. It can also increase production of IL-1, IL-6, TNF-α, and growth factors
[73, 92, 93]. TGF-β can inhibit epithelial cell proliferation, stimulate excess production
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of collagen from fibroblasts, and decrease collagen degradation thus contributing to
fibrosis.
Rube et al. [73] investigated the expression of TGF-β in C57/BL6 mice following 6 and
12Gy irradiation. After 12Gy mRNA expression of TGF-β was increased within one
hour and increased significantly above controls by 12hrs, and then subsequently declined.
It later peaked again at 2 and 4 weeks PI.

Levels of TGF-β correlated with

immunohistochemical staining of macrophages. Finkelstein et al. [20] also has shown
increases in TGF-β in C57/BL6 mice 14 days following 5 and 12.5Gy irradiation.
Anscher et al. [90, 92] investigated the prospects of using TGF-β as a marker for
development of pneumonitis in lung cancer patients treated with radiation therapy.
Plasma samples were obtained before, during and after each radiotherapy treatment. The
findings suggest that patients with lower levels of plasma TGF-β were less likely to
develop radiation pneumonitis. More recently, it was also shown that a small molecule
inhibitor of the type I TGF-β receptor was effective in reducing the extent of radiation
induced lung injury as assessed by breathing rate and histology [94]. These studies of
cytokine expression levels demonstrate that the radiation induced inflammatory response
follows a temporal pattern of expression that may be responsible for the development of
clinically apparent symptoms. The balance between pro and anti-inflammatory cytokines
may help to better understand the timing of the waves of inflammation.

1.11

Lung Inflammation Post Irradiation (PI) – NF-κB

Transcription factors also play an important role in the progression of the
inflammatory lung response following irradiation [71, 95, 96]. Nuclear factor kappa B

24

(NF-κB) has been shown to be continuously activated following irradiation and is
involved in initiating and sustaining the inflammatory response [97, 98]. NF-κB can be
activated by a wide variety of stimuli, such as oxidative stress, radiation, LPS exposure,
cytokines, bacterial and viral antigens, many of which are involved in the inflammatory
response. It also modulates a variety of cell functions including immune responses, stress
responses, cell cycle and survival, apoptosis and regulating inflammation. NF-κB is
involved in inflammation by regulating transcription of genes for pro and antiinflammatory cytokines [99-101]. NF-κB exists in a latent form in the cytoplasm as a
heterodimer bound to an inhibitory protein IκB. There are five proteins in the NF-κB
family; p50 and p65 are the most commonly found heterodimer. When NF-κB is
activated, extracellular stimulus leads to IκB kinase (IKK) phosphorylating IκB and thus
targeting it for ubiquitination and degradation by the proteasome (Figure 1-5). Free NFκB can then translocate to the nucleus and activate target genes by binding with high
affinity to κB elements in their promoters [102].

NF-κB is activated by radiation,

oxidative stess, and many products of the inflammatory lung response (cytokines,
macrophages, ROS) and further promotes the inflammatory response itself, thus playing a
key role in the regulation of the radiation response in lung.

NF-κB activation is

controlled by a negative feedback loop by upregulating production of inhibitory IκB.
NF-κB activation is also suppressed by anti-oxidants and anti-inflammatory cytokines
resulting in decreased pro-inflammatory mediator expression [103, 104].

1.12

Oxidative Stress

Normal tissue damage involves complex interactions between many cell types as
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Figure 1-5: NF-κB transcription pathway. There are five proteins in the NF-κB family, it is commonly
found as heterodimer composed of subunits p50 and p65 bound to inhibitory protein κB (IκB). Radiation
and other factors can initiate the NF-κB pathway by activating inhibitory κB kinase (IKK). IKK is a multisubunit enzyme composed of a heterdomer of IKKα and IKKβ, and regulatory subunit NEMO. The IKK
complex phosphorylates IκB and targets it for ubiquitination and degradation by the proteosome. The NFκB heterodimer is only then free to translocate to the nucleus to be transcribed. Figure modified from [105]
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described previously, however many of the mechanisms of interaction are still unknown.
One mechanism of cellular interaction following radiation is the bystander effect, which
has similarities to the out-of-field effect described by observations in our lab [27, 28].
The out-of-field effect is observed when tissue damage was located beyond the
boundaries of the irradiation field, and even within a different unirradiated lobe of the
lung. This is also similar to abscopal effects that are significant responses seen in tissues
definitively separate from the irradiated area [106]. The bystander effect is observed
when unirradiated cells exhibit responses associated with radiation exposure as a result of
cell-to-cell contact or through soluble signals [93]. Several experimental approaches
have been used to study this phenomenon. In vitro experiments used confluent cell
cultures to demonstrate direct intercellular communication through cell-to-cell contact.
Precise irradiation of target cells produced DNA mutations and micronuclei (MN)
formation in neighbouring unirradiated cells. MN formation occurs when portions of the
chromosome are lost due to double strand DNA breaks. A second approach transferred
culture medium from irradiated cells to a separate unirradiated flask and still observed the
radiation response [107]. This supports the notion that a soluble factor is capable of
initiating the radiation response in cells beyond the irradiation field. Both approaches
implicated enhanced oxidative metabolism with reactive oxygen species (ROS) and stress
response proteins as key factors [106].
One effect of the soluble signals of bystander effects and inflammation is
oxidative stress. Bystander effects have been partially attributed to the production of
ROS following irradiation that also stimulate cytokine production [108].

ROS are

reduced metabolites of molecular oxygen such as the hydroxyl radical (OH·), hydrogen
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peroxide (H2O2), and superoxide anions (O2-) that are continuously generated through
normal oxidative metabolism (Figure 1-6) and during radiation exposure [13, 107]. ROS
are oxidizing agents capable of causing DNA damage. Superoxide is a free radical that is
not highly reactive and can not cross lipid membranes and is restricted to the intracellular
compartment in which it is generated.

Superoxide is primarily generated in the

mitochondria due to leakage from the electron transport chain or by direct reduction of
molecular oxygen.

Superoxide is rapidly dismutated to hydrogen peroxide by the

antioxidant enzyme superoxide dismutase (SOD).

Hydrogen peroxide is not a free

radical and is a weaker oxidizing agent than superoxide; however, it can cross biological
membranes.

At low concentrations hydrogen peroxide is converted to water by

glutathione peroxidases, and at high concentrations it is converted to water and molecular
oxygen by catalase localized in peroxisomes.

In the presence of transition metals

hydrogen peroxide can give rise to the most reactive ROS, the hydroxyl radical, via the
Fenton reaction [13]. Reactive nitrogen oxide species (RNOS) are also produced from
the reaction of nitric oxide (NO·) with molecular oxygen or superoxide.
Irradiation of biological material leads to a burst of ROS production mainly due to
the ionization of water molecules. The hydroxyl radical is highly reactive and reacts
within 10-9s of generation. Superoxide anions and hydrogen peroxide are relatively
stable and can persist for 101-102s in water, however the amounts of these radicals
produced by radiation (depending on dose) is much lower than those produced by normal
cellular metabolism [109]. In addition to the rapid burst of ROS following radiation there
is a prolonged increase in ROS up to several days post irradiation [14]. The presence of
ROS can cause activation of transcription factors such as NF-κB, induce apoptosis or
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Superoxide formation:
O2 + e- → O2Hydrogen peroxide formation:
2 O2- + 2H+ → H2O2 + O2
Hydroxyl formation (Fenton reaction):
H20 → OH· + H·
Fe2+ + H2O2 → Fe3+ + OH-+ OH·

Figure 1-6: Reactive Oxygen Species (ROS) formation reactions
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necrosis, and alter signals regulating cell growth and signalling cascades. ROS can cause
damage to DNA, lipids, proteins and endothelial cells, and increase microvascular
permeability through their ability to induce biochemical alterations [110, 111]. This
supports the hypothesis that chronic oxidative stress plays a key role in inflammation and
tissue damage following irradiation. Irradiation induces production of ROS that cause
increased expression of CAMs on inflammatory cells, thus further recruiting
inflammatory cells to the site of injury. Macrophages and monocytes themselves are
major sources of cytokines and ROS and perpetuate the inflammatory process [110]. In
the context of radiation response, inflammation is initiated to try and repair initial
damage, but if the response is not regulated it can lead to chronic inflammation and
oxidative stress causing further tissue damage.

1.13

Protection Against Oxidative Damage – SOD and SOD mimetics
Cells and tissues protect themselves from the damaging effects of radicals and

ROS by intracellular defence mechanisms that form a redox buffer network with
molecules such as SOD, catalase, glutathione and related enzymes [112]. Many studies
have also focused on protecting against oxidative damage and reducing ROS levels using
agents similar to SOD. SODs are metalloproteins that can dismutate superoxide anions to
less reactive hydrogen peroxide and oxygen without extra input of cellular energy [111].
SOD enzymes exist endogenously in two forms: MnSOD found in the mitochondria, and
CuZnSOD found in the cytosol and extracellular space (EC-SOD) [113]. High levels of
EC-SOD are produced by type II pneumocytes in the lungs and other pathways [114].
Several studies have investigated the use of SOD to protect against the high levels of
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ROS formed after radiation. In our lab, it was demonstrated that administration of
MnSOD or CuZnSOD lowered the MN damage seen out of field, suggesting that MN are
produced by ROS and that the oxidative damage detected as MN can be modified by
these agents [27]. Transgenic mice over expressing EC-SOD were observed to show
greater protection against radiation induced lung damage as assessed by changes in
breathing rate frequency, macrophage accumulation, collagen deposition, TGF-β1
activity, and lipid oxidation.

The mice had an increased anti-oxidant capacity and

showed a decreased inflammatory response due to a decreased macrophage and TGF- β1
response [115, 116]. In addition, mice over expressing a transgene for human MnSOD
were also protected against radiation induced lung damage and showed decreased levels
of mRNA for IL-1, TNF-α, and TGF-β. Histological samples also showed that the mice
developed less severe alveolitis and fibrosis, as well as increased survival.

Over

expression of CuZnSOD did not confer any additional protection from radiation damage,
perhaps as it is not upregulated following irradiation and it is located in the cytosol away
from critical targets such as the mitochondria [117, 118].

The main limitation of

endogenous SOD is its large size (~30kDa) and its inability to cross cell membranes. In a
therapeutic approach, administration of endogenous SOD would only offer antioxidant
activity in the extracellular space and not within the cell itself. As a result, several
smaller molecular mass SOD mimetics that imitate the endogenous SOD functions have
been developed [111]. Since radiation creates ROS directly within the cell due to the
ionization of water molecules and mitochondria within the cell produce ROS, and
inflammation creates ROS outside the cell, it is important that protective agents be
effective in both locations (Figure 1-7). SOD mimetics therefore are likely to offer
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greater protection than endogenously administered MnSOD or CuZnSOD that acts
against extracellular ROS alone.
Studies in our lab with a manganese-salen SOD-catalase mimetic Eukarion189(EUK-189) showed that administration at early times following radiation lowered the
chronic production of ROS and reduced DNA damage seen during this period [119].
Other SOD-catalase mimetics, AEOL 10113 and 10150, have also been reported to
alleviate increases in breathing rate, TGB-β1 activity, hydroxyproline levels, and
collagen content following hemithoracic radiation in rats [120-122]. Two Mn porphyrinbased SOD mimetics also showed protective effects by scavenging ROS [123]. These
results suggest that at least some of the DNA damage is caused by oxidative stress
induced by the radiation-induced inflammatory response and that DNA damage caused
by this mechanism can be scavenged by protective agents.

1.14

Protection Against Lung Inflammation
One of the best radioprotectors if given before irradiation is amifostine

(WR2721), a thiophosphate compound. Amifostine has been shown to protect against
increases in breathing rate, increased plasma TGF-β, and fibrosis but is also known to
interfere with chemotherapeutics [124-127]. Studies of angiotensin converting enzyme
(ACE) inhibitors and angiotensin II receptor blockers, such as captopril, have shown
significant protection against radiation pneumonitis and fibrosis [128-133]. Captopril is
believed to reduce the effects of radiation on endothelial cells, fibroblasts and
macrophages, and regulate the blood pressure of the pulmonary artery thus lowering
edema in the lung. However, it has a very short half life of 2-3 hours. Pentoxifylline is a
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Radiation

Inflammatory response
ROS
Damage inside or
outside radiation field

Free radicals/ROS
Damage inside
radiation field

Figure 1-7: In and out-of-field effects of radiation. Radiation may act directly causing DNA damage
within the irradiation field (1) by directly ionizing DNA and water molecules. It may also act indirectly by
inducing an inflammatory response, that subsequently produces ROS that may cause damage in and out-offield.
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xanthine derivative that has shown potential to reduce radiation toxicity and has been
reported to reduce pneumonitis when given during radiotherapy in patients [134]. It has
also been shown to maintain perfusion in rats at late times following irradiation but had
little effect on pneumonitis or fibrosis [135, 136]. Given continuously before and after
radiation, pentoxifylline was shown to reduce levels of pro-inflammatory TNF-α in
mouse lung, and reduce the inflammatory cell infiltrate but it did not have an effect on
overall lung damage [72]. These results using amifostine and ACE inhibitors suggest that
modulating the inflammatory response could protect against tissue damage but further
investigation of other agents may prove to be more effective.
Using gene therapy, a study of soluble TGF-β receptor to decrease availability of
TGF-β1 by competitive inhibition examined if this approach could protect the lung from
radiation injury by modulation of the inflammatory response [89]. The study showed a
reduction in breathing rates, lower damage visible in histology samples, decreases in
macrophage accumulation and plasma TGF-β1 in treated animals. Blocking the proinflammatory cytokine’s ability to bind to its receptor prevented further signal
transduction and generation of late tissue damage.

In addition, plasma TGF-β1 of

patients has been shown to be significantly predictive of radiation-induced lung toxicity,
thus further implicating TGF-β1 as an important factor in lung radiation response [137].

1.15

Protection Against Radiation-Induced Lung Damage by Genistein
Genistein (4’5,7-trihydroxyisoflavone) (Figure 1-8) has anti-oxidant and anti-

inflammatory properties, has low toxicity and is commonly used as a dietary supplement
[138-140].

Genistein acts as an anti-oxidant by directly scavenging ROS [140].
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Genistein inhibits protein kinase activity and blocks activation of the transcription factor
NF-κB, a critical mediator of immune and inflammatory responses [141-144]. Genistein
has been reported to reduce acute lung injury from inflammation after lipopolysaccharide
treatment [142, 144]. Genistein has also been used as a radioprotector and has been
shown to increase survival following whole body irradiation [145].
radioprotection

studies,

genistein

has

been

investigated

as

In addition to
an

anti-cancer

therapeutic[146]. Diets high in soy isoflavones have been noted for their role in reducing
the incidence of breast and prostate cancers [147, 148]. Genistein inhibits carcinogenesis
in many tumour models through the modulation of genes for cell cycle, survival and
apoptosis [139, 146] and has been reported to reduce development of metastasis in breast
cancer and prostate models [149-151].
Previous work in our lab examined the protective effects of genistein in rats when
given following 18Gy whole lung irradiation. (Calveley et al, in preparation). In this
study the rats put on a genistein diet of ~10mg/kg/day demonstrated increased survival
during the early phase of pneumonitis and were partially protected against an increase in
breathing rate during this time. Genistein did not increase survival during the later
fibrosis phase and rats showed an increase in breathing rate during this time. However,
when examined at 28 weeks the surviving rats on the genistein diet did show reduced
levels of collagen in their lungs relative to animals given the control (low soy) diet.

1.16

Goals of Current Study
The goal of this study was to investigate the mitigation and treatment potential of

genistein combined with fractionated radiation therapy.

Chapter 2 describes these
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Figure 1-8: Structure of Genistein (4’5,7-trihydroxyisoflavone)
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experiments conducted with genistein.

Chapter 3 discusses the relevance and

implications of this work and presents future directions. The present study was designed
to follow up on the previous findings by investigating the effects of prolonged
administration of a genistein diet in mice following a more clinically relevant fractionated
irradiation treatment to the lungs. Previous studies had investigated effects following a
single dose of radiation, and fractionated doses had not been examined. While the
fractionation schedule was expected to be equivalent in terms of functional deficit, based
on isoeffect formulas [39, 40], the contribution of each fraction to the lung response and
the effect of genistein in this case were unknown.
Whenever an agent capable of protecting normal tissue is given, the potential to
also protect tumor tissue must also be examined, thus the potential of genistein to protect
tumor was also investigated. An ideal agent would protect the normal tissue and not
protect, or sensitize tumor to radiation. Previous studies in the lab had always used a rat
model, and the impact of genistein on tumor and radiation response had not been
examined. We switched to a mouse model for these studies both to allow examination of
whether tumour might be protected by the genistein treatment (by an established mouse
lung colony assay) and to provide information about the effects of genistein in a different
animal model.

37

2

Chapter 2: Mitigation of radiation-induced lung damage by Genistein

Data from this chapter was submitted for publication to
Radiotherapy and Oncology in September 2008
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2.1

Abstract

Background and Purpose: This study investigated protection of lung injury by genistein
following fractionated doses of radiation and its effect on tumor response.
Material and Methods: C3H/HeJ mice were irradiated (100 kVp X-rays) with 9 fractions
of 3.1Gy over 30 days (~10Gy single dose) and maintained on a genistein diet (~10
mg/kg.

Damage was assessed over 28 weeks in lung cells by a cytokinesis block

micronucleus (MN) assay and by changes in breathing rate and histology.

Tumor

protection was assessed using a colony assay to determine cell survival following in situ
irradiation of small lung nodules (KHT fibrosarcoma).
Results: Genistein causes about a 50% reduction in the MN damage observed during the
fractionated treatment and continues to decrease at late times to background levels by 16
weeks.

Genistein reduced macrophage accumulation by 22% and reduced collagen

deposition by 28%. There was minimal protection against increases in breathing rate or
severe morbidity during pneumonitis. No tumor protection by genistein treatment was
observed.
Conclusions: Genistein may partially reduce the extent of fibrosis developing in mouse
lung caused by irradiation but gives minimal protection against pneumonitis at this dose.
There is no evidence that genistein causes protection of small tumors growing in the lung.

2.2

Introduction
The thorax is commonly irradiated for treatment of lung cancer, breast cancer, and

various lymphomas. The lung is a relatively radiosensitive organ [3] and normal tissue
tolerance is a dose limiting factor in radiotherapy of the thoracic region [4].

It is
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desirable to give the highest possible dose to the tumor while sparing the surrounding
healthy normal tissue and managing normal tissue complications.

Approaches to

protecting or mitigating the effects of radiation on lung tissue might improve the
therapeutic ratio and have been investigated in a number of centres [45, 119, 121, 123,
133]. Radiation-induced lung injury has classically been separated into two phases:
pneumonitis and fibrosis. Pneumonitis is an acute inflammatory reaction that occurs two
to four months following irradiation where there is an increase in oedema and
inflammatory cells causing cough and dyspnea. Fibrosis begins four to six months post
irradiation characterized by progressive scarring of the lung, with vascular cell damage
and collagen deposition causing chronic dyspnea [4]. Fibrosis increases over time and
reduces the functional capacity of the lung. In thoracic radiotherapy, dose escalation is
limited by the normal tissue complication probability (NTCP). Using current treatment
protocols, the risk of radiation pneumonitis is of most concern as it has considerable
impact on patient morbidity and mortality [16, 137, 152-155].
Before symptoms are clinically evident there are molecular changes in response to
radiation that are believed to underlie the development of pneumonitis and fibrosis.
Direct radiation damage to individual lung cells is compounded by a complex cycle of
inflammation and altered expression of cytokines, that causes production of reactive
oxygen species (ROS) resulting in oxidative damage [7, 27, 44, 70].

Alveolar

macrophages, lung fibroblasts, type II pneumocytes and endothelial cells interact via
cytokine and growth factor signalling [8, 9]. There is an increase in levels of intercellular
adhesion molecule-1 (ICAM-1) and E-selectin in lung endothelial cells allowing for
increased arrest of inflammatory cells in lung capillaries [156]. Many studies have
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documented changes in cytokine expression following irradiation, in particular temporal
upregulation of the inflammatory cytokines interleukin-1alpha (IL-1α), interleukin-1beta
(IL-1β), transforming growth factor-beta (TGF-β), and tumour necrosis factor-alpha
(TNF-α) have been documented [6, 10, 77, 84, 157]. Temporal changes in expression
depend upon the experimental system, but can be seen as early as one hour following
irradiation and continue over the course of development of pneumonitis and fibrosis [11,
15, 44, 71-74].
The severity of side effects following irradiation depends upon volume and region
irradiated, dose and fractionation regimen, and concurrent chemotherapy agents. The
base of the lung has been shown to be more sensitive than the apex [23, 27-30, 33, 36]
and the left lung is more sensitive than the right [27, 28, 158]. In addition to the locoregional response and volume effects, the inclusion of the heart in the radiation field may
increase damage seen in the lung [34, 35, 159]; however, this effect was not observed in
some other studies [25, 33].

Previous studies in our lab using partial lung irradiation

have shown there is DNA damage in and out of the radiation field [27, 28]. This supports
the idea that some DNA damage may be caused by the action of inflammatory cytokines
and the resultant production of ROS. Administration of superoxide dismutase (MnSOD,
CuZnSOD) lowered the damage seen out of field, demonstrating that oxidative damage
can be modified by these agents. Furthermore studies with the manganese-salen SODcatalase mimetic Eukarion-189 (EUK-189) showed that administration at early times
following radiation lowered the chronic production of ROS and reduced DNA damage
seen during this period [119]. In addition, transgenic mice over expressing extracellular
(EC)-SOD in alveolar and airway epithelial cells showed protection from radiation injury
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due to an increased anti-oxidant capacity and decreased inflammatory response [116].
Mice over-expressing a transgene for human MnSOD were also protected against
radiation-induced lung injury [117, 118].
Our current study investigates the mitigation and treatment potential of the soy
isoflavone genistein as a therapeutic agent when combined with radiation. Genistein
(4’5,7-trihydroxyisoflavone) has anti-oxidant and anti-inflammatory properties, has low
toxicity and is commonly used as a dietary supplement [138-140]. Genistein inhibits
protein kinase activity and blocks activation of the transcription factor NF-κB, a critical
mediator of immune and inflammatory responses [141]. Genistein has been reported to
reduce acute lung injury from inflammation after lipopolysaccharide treatment [142] and
administration of genistein doses up to 400mg/kg provided a significant increase in
survival following whole body irradiation without any toxicity [145]. In addition to
radioprotection studies, genistein has been investigated as an anti-cancer therapeutic.
Diets high in soy isoflavones have been noted for their role in reducing the incidence of
breast and prostate cancers [147, 148]. Genistein inhibits carcinogenesis in many tumour
models through the modulation of genes for cell cycle, survival and apoptosis [139, 146]
and has been reported to reduce development of metastasis in a breast cancer model
[149].
Previous work in our lab examined the protective effects of genistein in rats given
following 18Gy whole lung irradiation. (Calveley et al, in preparation). In that study the
rats were fed a genistein diet of ~10mg/kg/day, and demonstrated increased survival
during the early phase of pneumonitis and were partially protected against an increase in
breathing rate during this time. Genistein did not increase survival during the later
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fibrosis phase and rats showed an increase in breathing rate during this time. However,
when examined at 28 weeks the surviving rats on the genistein diet did show reduced
levels of collagen in their lungs relative to animals given the control (low soy) diet. The
present study was designed to follow up on these findings by investigating the effects of
prolonged administration of a genistein diet in mice following a more clinically relevant
fractionated irradiation treatment to the lungs and to provide information about the effects
of genistein in a different animal model. This study also examined whether tumour might
be protected by the genistein treatment.

2.3

Materials and Methods

Mice
For the initial short-term experiments examining MN formation following
irradiation both female C57Bl/6J and female C3H/HeJ mice (JAX Laboratory) aged 7
weeks were used. For the long term studies, only female C3H/HeJ mice ages 7 weeks
(JAX Laboratory) were used because of their known sensitivity to the development of
pneumonitis and later fibrosis whereas C57Bl/6J are fibrosis prone but lack the
pneumonitis response [81, 86, 160]. The animals were housed at the Ontario Cancer
Institute/Princess Margaret Hospital small animal facility, which is accredited by the
Canadian Council on Animal Care and were treated in accordance with approved
protocols. Mice were randomly assigned to one of four treatment groups: radiation and
genistein, radiation and control diet, sham radiation and genistein, sham radiation and
control diet. At each experimental time point (4, 8, 12, 16, 20, 24 and 28 weeks) a group
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of four randomly selected mice in each group was sacrificed for analysis unless otherwise
indicated.

Irradiation
Mice were irradiated with a dual headed 100 kVp X-ray unit [161], operating at
10mA with a dose-rate of approximately 10.2Gy/min. Nine fractions of 3.1Gy were given
over 30 days (3-4 days apart). This dose had been previously shown to produce a
functional deficit equivalent to a 10Gy single dose and to be equivalent to more extended
fraction schedules in terms of lung damage in rats [39, 40].

The RBE of X-rays

compared to Cesium was found to be approximately 1.2 assessed by tumor cell killing in
vivo (unpublished data). Day 1 was set as the first day of radiation treatment. Prior to
irradiation the mice were anaesthetized by halothane inhalation and placed in customdesigned lucite holding containers.

A digital x-ray unit was used to position lead

shielding around the lungs to provide a circular field of 2.5cm diameter for irradiation.

Genistein Treatment
During the course of the experiment, mice were provided with sterilized food and
water ad libitum. The AIN-76A diet (Harlan Teklad, Madison, WI, ref [162]), a semi
purified casein-based diet containing no detectable phytoestrogens (limit of detection,
5pmol/mL) was selected as the control diet. The genistein diet was formulated from the
control diet, supplemented with 750mg/kg of genistein and has been used by others
[149]. This concentration has been shown to yield serum Genistein levels in mice (~12μmol/L) similar to those observed in humans consuming a diet containing modest
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amounts of soy products(1-2 servings) [163]. Genistein was chemically synthesized
(Toronto Research Chemicals Inc, Toronto, Ontario) and incorporated into the AIN-76A
diet at Harlan Teklad.
delivered.

Dietary consumption was monitored to calculate the dose

Mice were monitored for radiation toxicity and were sacrificed when

moribund. Mice were weighed weekly following radiation and mice losing >20% body
weight, or exhibiting signs of distress such as ruffled fur, very rapid breathing, and
hunched posture were sacrificed.

Micronucleus Assay
A well established cytokinesis block micronucleus(MN) assay [27, 28] was used
to assess genomic damage following irradiation.

Briefly, Alpha MEM medium

supplemented with antibiotics (Sigma-Aldrich Canada Ltd, Oakville, Ontario, Canada)
was injected into the right ventricle of deeply anaesthetized mice to perfuse the lungs and
remove as much blood as possible. The right lungs were then aseptically removed and
minced and digested with 0.25% trypsin and 0.25% collagenase I (Gibco, Invitrogen
Corporation, Burlington, Ont., Canada), at 37ºC for 2 hours. The digested tissue was
filtered, centrifuged and resuspended in Alpha MEM with 10% fetal calf serum (FCS).
The cells were plated in chamber slides and incubated at 37ºC. After 24 hours, culture
medium was replaced with complete medium containing cytochalasin B (Sigma-Aldrich
Canada Ltd, Oakville, Ontario, Canada) to inhibit cytoplasmic division without
interfering with nuclear division. After another 72 hours of incubation, the cells were
fixed with KCl and then methanol. Slides were stained with acridine orange (SigmaAldrich Canada Ltd, Oakville, Ontario, Canada) and scored as the number of MN per
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thousand binucleated (BN) cells. MN were scored if they were distinguishable from the
main two nuclei, less than one third the size of the main nuclei and had similar staining
intensity [164]. Background levels of MN were consistently 15-50 MN/1000BN cells.

Lung extraction
Mice were deeply anaesthetized and using the “Inflation procedure for open lung
biopsies”[165] the left lung was injected with 5ml 10% formal saline via the left main
bronchus in order to expand the alveoli. The lung was then removed and placed in 10%
formaline saline for 48 hours for fixation. The lungs were embedded in paraffin and
sections 5μm thick were cut and placed on slides in preparation for staining.

Immunohistochemistry
Sections were stained with Haematoxylin and Eosin (H and E), Masson’s
Trichrome for collagen content and the MAC3 antibody for activated macrophages in the
Pathology core facility of the Ontario Cancer Institute. Sections were analyzed with the
positive pixel algorithm in Aperio ImageScope (Aperio Technologies Inc.) The mean
percent positive pixels stained are presented.

Breathing rate
The breathing rate of mice was measured at 0, 4, 8, 10, 11, 12, 13, 14, 16, 18, 20,
22, 24, 28 weeks following irradiation using a whole body plethysmograph (Columbus
Instruments, Columbus, Ohio). Increases in breathing rate have been previously shown
during pneumonitis and fibrosis [23, 30, 166-168]. Mice were acclimatized to the
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measurement process three times before the commencement of the experiment. Mice
were allowed to acclimatize before each measurement for one minute. Data for each
mouse were collected for one minute and at least 3 readings from 4 second periods were
selected by hand from regions free of noise due to movement of the mouse in the
measurement chamber. Data are represented as the mean +/- SE.

Impact of Genistein on Tumor Response to Radiation
C3H/HeJ female mice were injected intravenously with 2*104 KHT murine
fibrosarcoma cells into the tail vein (IV). The tumor cells then arrest in the lungs and
tumors were allowed to grow for either 2 or 10 days (approximate nodule size at 2 days
<1mm, at 10 days ~3mm). Mice were then treated with a single dose of 5Gy while lung
radiation combined with a single dose of genistein at 12.5mg/kg intraperitoneally (IP). A
separate group of mice were put on the genistein diet and irradiated with 9 daily fractions
of 3.1Gy whole lung irradiation commencing 8 days following KHT injection. Twentyfour hours following the last fraction, the lungs of the mice were removed aseptically,
minced and digested in 0.5ml trypsin, 4.8ml PBS and 45 Kunitz units DNase I (SigmaAldrich Canada Ltd, Oakville, Ontario, Canada) for 30 minutes at 37ºC. The tissue was
strained and rinsed with PBS and re-digested in 0.5ml 0.25% collagenase I, 45 Kunits
DNase I, and 4.4ml Alpha MEM + 10%FCS at 37ºC for 2 hours. The suspension was
strained, centrifuged, and resuspended in alpha MEM +10% FCS, cells were counted and
plated. Colonies were allowed to grow for 10 days and then fixed with methanol. Tumor
cell colonies greater than 50 cells were scored and the number of colonies recovered per
lung was calculated.
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Data Analysis
When comparisons were made between the means of two groups, a two tailed
Student’s t-test was used, p<0.05. For multiple comparisons an ANOVA was used
followed by testing of individual groups via Tukey’s test, p<0.05.

2.4

Results

Normal Tissue Response
Food consumption and toxicity
The mice were weighed to monitor their health and toxicity of treatment (Figure
2.1). The food consumption was also monitored. The average consumption of food per
mouse was 2.71 (±0.08)g food per mouse per day similar to that reported previously
[149]. From the diet formulation the mice were consuming approximately 2.03mg of
genistein per day. The control mice steadily gained weight as they grew during the
course of the experiment. The irradiated animals maintained or lost weight during the
fractionated treatment but began to gain weight at a similar rate to the controls after
radiation treatment was finished. The control animals on the genistein diet were slightly
heavier than those on the control diet.

Micronucleus formation
C57/Bl6 (F) and C3H/HeJ (F) mice were irradiated with 9 fractions of 3.1Gy over
30 days to the thoracic cavity and given either the control diet or the diet containing
genistein starting 2 days before the first fraction. Mice were sacrificed 18 hours post
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Figure 2-1: Weight of mice following irradiation. The irradiated groups did not gain weight during the
irradiation treatments. After irradiation all mice gained weight at roughly the same rate. Weights were
used to monitor the health of the mice. This shows no toxicity associated with genistein in the diet.
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irradiation after the 1st, 3rd, 6th and 9th fractions. Comparisons were also made between
unirradiated controls and mice treated with a 10 Gy single dose. Genistein was effective
in reducing the MN damage observed in normal lung fibroblasts of each irradiated group
by an average 47% in C57/Bl6 mice and by 46% in C3H/HEJ mice (Figure 2.2). The
level of damage observed in the fractionated groups was less than that of a single dose,
and increased according to total dose delivered. There was no significant increase in MN
formation between the 6th and 9th fractions. The background level of MN is less than 50
MN/1000BN cells.
C57/Bl6: Mice were analyzed with no treatment (n=4 per group), post 10 Gy single dose
(n=4 control, n=3 genistein), post fraction 1 (n=4 control, n=3 genistein), post fraction 3
(n=3 control, n=4 genistein), post fraction 6 (n=7 control, n=4 genistein), post fraction 9
(n=7 control, n=4 genistein). Comparison between control and treated groups: no
radiation p=ns, 10Gy single dose p=0.001, fraction 1 p=0.009, fraction 3 p=0.001,
fraction 6 p=0.001, fraction 9 p=0.045. Average reduction in MN formation by genistein
=47%.
C3H/HEJ: N=4 mice for all groups. Comparison between control and treated groups: no
radiation p=ns, 10Gy single dose p<0.001, fraction 1 p=0.003, fraction 3 p<0.001,
fraction 6 p=0.002, fraction 9 p=0.048. Average reduction in MN formation by genistein
=46%.
C3H/HEJ (F) mice irradiated with 9 fractions of 3.1 Gy were also followed for 28
weeks to examine the long term effects of the genistein diet on radiation damage (Figure
2.3). Following radiation genistein reduced MN formation to background levels by 16
weeks post irradiation. The irradiated mice on the control diet had sustained levels of MN
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formation between 300-400MN/1000BN for weeks 12-28, well above the background
levels. N=4 mice for all groups. Comparison between irradiated treated groups: 4 weeks
p=0.048, 8 weeks p=0.021, 12 weeks p=0.035, 16 weeks p=0.018, 20 weeks p=0.009, 24
weeks p<0.001, week 28 p=0.001. There was no significant difference between the sham
treatment groups. From weeks 16-28 there was no significant difference between the
irradiated genistein and the sham groups.

Immunohistochemistry
The left lungs were fixed in formalin and stained for histology and
immunohistochemistry. At early times up to 4 weeks there were no visible changes in
intra-alveolar thickness, alveolar spaces or inflammatory infiltrate, collagen or activated
macrophages (data not shown).

For later times from 4-28 weeks post irradiation,

representative images of MAC3 staining for activated macrophages are shown in Figure
2.4. Additional images from moribund mice that were sacrificed in weeks 12, 14, and 16
and stained with MAC3 are also shown in Figure 2.5.
MAC3 staining increased gradually over time in the sham groups while the
irradiated groups showed a 1.8x increase over the unirradiated controls (Figure 2.6).
Genistein caused a significant reduction in macrophage content between the radiation and
control diet vs radiation and genistein diet at 28 weeks, and between the sham and control
diet vs. sham and genistein diet at 16 weeks. There was an average reduction of 22% in
macrophage content by genistein in the irradiated groups, and 45% in the sham groups.
Macrophage content was also quantified in moribund mice that were sacrificed early
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Figure 2-2: Micronucleus yield from whole lung irradiations in C57/Bl6 and C3H/HEJ mice at
various times during fractionated irradiation with genistein treatment. Each bar represents the
mean ± SE. N=3-7 mice per group. Genistein reduced MN formation in all groups.
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Figure 2-3: Micronucleus formation at various times following fractionated irradiation (9 fractions of 3.1
Gy) with genistein treatment. Each bar represents the mean ± SE. N=4 mice per group. Genistein reduced
MN formation at late times to background levels by 16 weeks PI.
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Figure 2-4: Representative images of MAC3 stain at 4 week intervals post irradiation. Black bar
represents 100μm. Activated macrophages stain brown. Irradiated animals show patchy inflammatory
infiltrate into the lung tissue and alveolar air spaces.
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Figure 2-5: Representative images of MAC3 stain at 12, 14, and 16 weeks post irradiation from moribund
mice that were sacrificed. Black bar represents 100μm. Inflammatory infiltrates completely obliterated
much of the normal lung tissue architecture.

55

20
18

Positivity (%) +/-SE

16
14
12

*

10

Radiation + Control Diet
Radiation + Genistein Diet
Sham + Control Diet

8

Sham + Genistein Diet

6
4

*

2
0
4

8

12

16

20

24

28

Weeks Post Irradiation

Figure 2-6: Quantification of MAC3 antibody staining (Figure 2-4) for activated macrophages content at 4
week intervals following fractionated irradiation (n=4 per group). Each bar represents the mean positivity
± SE. There is an average increase by 1.8x in macrophage content in the irradiated vs sham groups.
Genistein caused a significant reduction (*) in macrophage content between the Radiation and Control diet
vs Radiation and Genistein diet at 28 weeks, and between the Sham and Control diet vs. Sham and
Genistein diet at 16 weeks. There was an average reduction of 22% in macrophage content by Genistein in
the irradiated groups, and 45% in the sham groups.

56

35
30

% Positivity

25
20

Radiation + Control Diet
Radiation + Genistein Diet

15
10
5
0
12

14

16

Weeks Post Irradiation

Figure 2-7: Quantification of MAC3 staining for activated macrophages (Figure 2-5) for sacrificed
moribund mice from weeks 12, 14 and 16. Mice that were sacrificed early showed much higher levels of
macrophages than mice that were healthy at that time(ie mice that were randomly chosen for timepoint
analysis as shown in Figure 2-6). Each bar is one mouse.
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during weeks 12, 14, and 16 (Figure 2.7). These mice showed higher macrophage
content than mice that were healthy during the same time period.

Collagen content was assessed by Masson’s Trichrome staining as shown in
Figure 2.8. The levels in the unirradiated mice were fairly constant over the course of the
experiment while the irradiated groups showed an average 2.9x increase over the
unirradiated controls (Figure 2.9). The collagen content of the genistein groups was
reduced by approximately 28% from the control diets.

Functional Deficit
Breathing rate was measured as an indicator of functional deficit caused by
radiation damage (Figure 2.10). The irradiated groups both show an increase in breathing
rate during weeks 10-16 weeks post irradiation during the pneumonitis phase. Following
this time there was a sustained increase in breathing rate during the development of
fibrosis in weeks 18-28 in both irradiated groups with no obvious difference between
them.

Morbidity
Severe morbidity leading to animal sacrifice following the radiation treatment of
the mice was also assessed (Figure 2.11). There was no difference between the genistein
vs control diet groups with both showing a sharp decrease in survival during the
pneumonitis phase. The protection seen against MN formation in fibroblasts did not
extend to increased overall survival.

58

Figure 2-8: Representative images of Masson’s Trichrome stain at 4 week intervals post irradiation. Black
bar represents 100μm.

59

16
14

Positivity (%) +/-SE

12
10

Radiation + Control Diet

8

Radiation + Genistein Diet
Sham + Control Diet

6

Sham + Genistein Diet

4
2
0
4

8

12

16

20

24

28

Weeks Post Irradiation

Figure 2-9: Quantification of Masson’s Trichrome stain (Figure 4) for collagen content at 4 week intervals
following fractionated irradiation (n=4 per group). Each bar represents the mean positivity ± SE. There
was a trend for reduced collagen content in the irradiated Genistein group compared to the irradiated
control group, and in the sham Genistein compared to the sham control group. This trend was not
statistically significant; however, there was an average reduction in collagen content by 28% between the
irradiated groups and by 32% between the sham groups.
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Figure 2-10: Mean Breaths per Minute (BPM) +/- SE of irradiated vs control mice on Genistein and
Control diets (n=15-20 per group). The irradiated groups both show an increase in breathing rate during
weeks 10-14 weeks post irradiation during the pneumonitis phase, there is a light decrease from weeks 1416 then a sustained increase over the fibrotic phase in weeks 18-28. Both unirradiated groups have BPM
below 300.
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Figure 2-11: Survival of irradiated animals on Genistein vs Control diets (n=60 for both groups). Both
groups had a sharp decrease in survival between 8-16 weeks (2-4 months) during the pneumonitis phase.
There was no significant difference between the survival curves (Kaplan-Meier).

62

Impact of Genistein on Tumor Response to Radiation
Mice were injected with KHT tumor cells IV and tumors were allowed to grow in
the lungs for 2 or 10 days. The mice were then treated with a single dose of 12.5 mg/kg
genistein and/or 5Gy radiation to the thoracic cavity. Lungs were removed and assessed
for clonogenic survival. At 2 days or 10 days there was no difference in tumor cell
survival between the groups given a single dose of radiation (data not shown). For
fractionated radiation treatment the mice were put on the genistein diet at day 8 after cell
injection and maintained on this diet for the remainder of the experiment. The mice were
irradiated with 9 daily fractions of 3.1Gy starting on Day 8. There was a significant
reduction in colony formation in genistein treated mice in the un-irradiated and irradiated
groups (Figure 2.12) suggesting that prolonged treatment with genistein may reduce the
growth rate of the lung nodules. Genistein caused a reduction in the number of tumor
cells recovered following radiation, but its effect as a radiosensitizer was not statistically
significant.

2.5

Discussion
Fibrosis and particularly pneumonitis are serious side effects that are dose

limiting in radiotherapy involving significant volumes of the lung. This study examined
the potential protective effects of genistein on early and late effects post irradiation
through comprehensive assessment of DNA damage, immunohistochemical analysis of
collagen content and macrophage activation and functional deficit in the whole organism
using a mouse model known to be prone to radiation-induced pneumonitis.
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Figure 2-12: Clonogenic assessment of tumor response following in situ irradiation of KHT tumors with
9x3.1Gy (n=6 per group). Genistein significantly reduced tumour formation in both irradiated (p=0.021)
and unirradiated groups (p=0.040). Effect of radiation vs. effect of Genistein: Genistein did not
significantly increase tumor sensitivity to radiation.
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Genistein protected against DNA damage as assessed by MN formation in normal
lung fibroblasts by greater than 50%. As the experiment progressed to later times, the
MN levels detected were reduced to background levels by 16 weeks post irradiation.
Genistein also reduced the macrophage content in lung tissue assessed by MAC3 staining
by ~22% and the deposition of collagen by ~28% as assessed by Masson’s Trichrome
staining. However, protection against DNA damage and MN formation did not extend to
significant protection against increases in breathing rate or decreased severe morbidity.
Both the genistein-treated and control animals treated with radiation showed a large
increase in breathing rates and approximately 45% of the animals manifested severe
morbidity during weeks 10-16. Histological samples showed that these mice were
suffering from severe pneumonitis.
The data demonstrating that DNA damage can be alleviated by genistein
treatment is consistent with our previous work that has shown similar effects in rats with
a SOD-Catalase mimetic EUK-189 following lower half lung irradiation [119]. The
previous work also showed that there appeared to be some regeneration of damage after
EUK-189 treatment and ongoing studies in rats indicate that genistein can partially
protect against pneumonitis in a rat model (Calveley et al., in preparation 2008).
Similarly, another SOD- catalase mimetic has also been reported to alleviate increases in
breathing rate and collagen content following hemithoracic radiation in rats [120-122].
These results suggest that at least some of the DNA damage is caused by oxidative stress
induced by the radiation-induced inflammatory response and that DNA damage caused
by this mechanism can be scavenged by EUK-189 or genistein when given after
irradiation.
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Oxidative stress, inflammatory cell recruitment and cytokine production
following radiation to the lung has been examined in many studies and postulated to play
a major role in the development of functional lung damage [169]. It was thought that
genistein would be an ideal agent to treat radiation-induced lung damage as it has both
anti-oxidant and anti-inflammatory properties (blocks activation of NFκB). Furthermore
it has been reported to reduce the inflammatory response induced by LPS [141]. Despite
this we found that although genistein was effective in reducing DNA damage in lung
fibroblasts, this did not relate to the functional outcome in our murine model.
One possible explanation for these results may be the source of ROS causing
DNA damage that is detected by the MN assay. There are at least three potential sources
of ROS within the irradiated lung, first that which is produced as a direct result of
radiation, second that is generated by inflammatory cells [12, 170], and third from the
mitochondria because of leakage from the electron transport chain [14]. Using whole
lung irradiation it is difficult to distinguish between these sources; however, previous
studies in our lab using half lung irradiation of rats [27, 28, 119] showed significant DNA
damage both in and out of the radiation field. We also found that MnSOD or CuZnSOD
and nitro-L- arginine methyl ester (L-NAME) were effective in protecting against out of
field damage. We hypothesized that these results could be explained if out-of-field
damage could arise from ROS (or RNOS) created by the induced inflammatory response
and in-field DNA damage could be induced by this mechanism as well as by ROS
generated primarily from the ionization of water and direct ionization of target molecules
[171]. Alternatively or additionally, since we have observed that DNA damage following
whole lung irradiation can be regenerated following scavenging by SOD-catalase
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mimetics or genistein [7] (and unpublished observations) the in-field DNA damage
observed may also be generated by ROS from the mitochondria. Mitochondrial ROS
have not been directly linked to induction of inflammatory responses and might be less
important for fibrosis development than extracellular ROS produced by inflammatory
cells.
It may also be important that inflammatory cells can produce several orders of
magnitude more ROS than would be produced directly by radiation doses of the size we
are using [170, 172]. Thus the levels of genistein used in the current studies may be
sufficient to reduce intracellular ROS (RNOS) to low levels but may be insufficient to do
this for extracellular ROS produced by the induced inflammatory response. Furthermore,
there are other mechanisms that may contribute to the chronic inflammatory response.
Mast cells, macrophages and neutrophils, that have been reported to be increased in C3H
mice with alveolitis [82, 173, 174] have been shown to secrete chemokines such as IL-6,
enzyme-rich granules and active amines which promote recruitment and infiltration of
other inflammatory cells along with increases in IL-1α/β and TNF-α. These cell types are
presumably attracted to the irradiated lung by expression of surface adhesion molecules
such as ICAM-1 or E-selectin [47, 156]. It has also been suggested that tissue hypoxia
may result from increased oxygen consumption by activated macrophages and decreased
perfusion due to vascular injury. Hypoxia may then further enhance oxidative stress by
inducing hypoxia inducible factor (HIF)-1α and downstream genes VEGF and
angiotensin II furthering inflammatory cell recruitment [170]. All of these possibilities
suggest that the use of higher doses of genistein may be required to achieve significant
effects on functional deficits following lung irradiation.
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A further possibility is that DNA damage to the lung fibroblasts is not critical for
functional outcome. It has been shown that radiation causes premature terminal
differentiation of fibroblasts causing increased synthesis and extracellular deposition of
collagen [175]. Since such cells become post mitotic they may harbour DNA damage
undetected by the MN assay while still contributing to the progression of tissue
remodeling and altering recruitment of inflammatory cells. However, many fibroblasts
still retain their ability to divide as we are still able to detect dose dependent DNA
damage by the MN assay.

Furthermore, studies in rat lungs exposed to internal

irradiation showed that deep lung epithelial cells also demonstrated significant levels of
MN as well as fibroblasts, indicating that the presence of DNA damage that can be
expressed as micronuclei in irradiated lung is not limited to fibroblasts [176].
An important question is why we observed little or no protection against
pneumonitis in the C3H mice when we had previously seen protection against this
endpoint in rats using an identical genistein containing diet. One possibility is the
pharmacokinetics of the compound. The amount of food consumed by the mice was
monitored and the approximate dose of genistein consumed was in the range of 80 mg/kg
per day (each mouse consumed 2.03 mg/day per 25 g) which has been reported to give a
plasma level in the range of 1-2 μmol/L [149]. Studies in rats of plasma values of
genistein given a dose of 50 mg/kg/day gave values of about 11 μmol/L [177], which are
significantly higher than the values reported for mice on the diet that we used. However,
the technique of genistein measurement and the administration methods are different so it
is difficult make a direct comparison. Nevertheless, a recent study of the effect of
genistein in bone marrow protection following 9.5Gy whole body irradiation showed a
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range of responses according to dose [145]. At least 25mg/kg was needed to produce an
effect on survival, and 91% survival was observed at 200mg/kg compared to 8% with
saline treated controls. A following study also showed protection against MN formation
and collagen deposition [178]. These considerations again suggest the need to test higher
doses of genistein. Particularly this may be true because the dose of genistein used in our
studies was chosen based on 1) studies in rats to determine the minimum dose which
would effectively scavenge all the DNA damage (micronuclei) when given after
irradiation. (Calveley et al in preparation) and 2) reports that the median intake of
isoflavones is 30-40mg/day in Asian populations, and that genistein levels in plasma
from Asian populations are in the range of 500nmol/L [179, 180].
Finally, whenever any protective agent is given in combination with radiation
therapy there is a concern that it may protect tumour as well. Consequently this study
also investigated the effect of genistein on in situ irradiated KHT tumours. We found that
there was no evidence of tumour protection. In fact there was a trend towards tumor
sensitization by the reduction in clonogenic cells recovered from unirradiated and
irradiated mice with prolonged treatment with genistein. This is consistent with other
reports that genistein has shown potential as an anti-cancer agent in several different
cancer cell types such as glioma [181], prostate cancer [150], lung cancer [182], cervical
cancer [183] and breast cancer [149]. Our results contribute to evidence that even as an
anti-oxidant genistein may be used safely as a protective agent for normal tissue in
combination with radiation therapy. These findings are encouraging but in the particular
case of the use of genistein (at higher doses) as a potential agent to protect lung tissue this
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experiment should be repeated using a human lung carcinoma cell lines to ensure that the
result is not cell type specific.
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3

Chapter 3: Discussion and future directions
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3.1 Discussion
Pneumonitis and fibrosis are severe side effects of radiation therapy that can occur
following irradiation of the lung. The probability of normal tissue complications is a
dose limiting factor for radiation that can be delivered. Reducing or preventing of side
effects would allow for dose escalation and better local control of the tumor. An agent,
such as genistein, may be beneficial to the treatment strategy by protecting against the
development of radiation pneumonitis and fibrosis in lung. New treatment regimes using
hypofractionation use 1-5 very large fraction sizes of up to 20Gy versus traditional ~30
fractions of 2 Gy daily. These potentially produce greater side effects, and minimizing
them would be highly beneficial.
The exact mechanisms of radiation induced lung damage are unclear.

It is

hypothesized that oxidative stress, inflammatory cell recruitment and cytokine production
following radiation to the lung play a major role in the development of functional lung
damage. Genistein is an ideal agent that acts as an anti-oxidant by scavenging ROS, and
as an anti-inflammatory by blocking activation of NF-κB. This study examined the
protective effects of genistein on early and late effects post irradiation through
assessment of DNA damage by MN assay, immunohistochemical analysis of collagen
content and macrophage activation and functional deficit using a mouse model known to
be prone to radiation-induced pneumonitis.
This study extended previous work in rat lung to a mouse model which had not
been used for long term studies before.

This study also moved to a fractionated

irradiation schedule to investigate protection against a more clinically relevant treatment.
Previous work in rats used a 18Gy (at a dose rate of 0.4-05Gy/min) whole lung
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irradiation which was the approximate LD50. This current study based the fractionated
treatment schedule on equivalent dose experiments [39, 40] and aimed to deliver a dose
equivalent to 10Gy, the LD50 for C3H mice. The current study used 100kVp x-rays at a
dose rate of ~10.2 Gy/min. The dose equivalence studies were performed in rats but the
overall survival in this experiment with the C3H mice was indeed close to 50% showing
that this fractionated treatment was closely equivalent in dose as expected.
The effectiveness of genistein in blocking DNA damage was assessed by levels of
MN formation. It was shown that genistein reduced MN formation by 50% in lung
fibroblasts over the course of fractionated treatment. Fractionation should allow for
repair of damage between doses, but measurements following the first, third, sixth and
ninth fractions all showed damage roughly half that of the untreated animals, and damage
increased with dose. The damage produced by each fraction was additive, and there were
high levels of MN formation following the 9 treatments comparable to damage seen
following a 10Gy single dose. The % reduction of MN formation was lowest after the 9th
fraction.
Lung fibroblasts from mice sacrificed at 4 week intervals post irradiation (PI)
showed decrease in MN formation over time to background levels by 16 weeks PI.
Previous studies with genistein in our lab showed that doses as low as 12.5mg/kg
genistein given intraperitoneally (IP) either 1 hour pre or 5 minutes post irradiation was
sufficient to reduce MN formation in rat lung to background levels in animals sacrificed
18hrs PI (Calveley, unpublished data). The genistein diet was formulated based upon the
results of these studies and aimed to deliver a dose of 12.5mg/kg absorbed. It was also
thought that providing genistein in the diet would provide better protection as it would be
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consumed at many times during the day and would give a more steady concentration
versus a single injection that has a half life of approximately 8 hours. The genistein diet
formulation was not as effective in fully blocking MN formation (only a 50% reduction
was observed following each fraction) as the IP injections, suggesting that for maximal
protection the dose of genistein being consumed in the diet should be increased. The
time course study of MN formation at 4 week intervals also provided insight into levels
of damage occurring over time.

Another previous study of 10Gy lower half lung

irradiation in rats saw fluctuating levels of MN over time[15] but that effect was not seen
in this experiment. Calveley (in preparation) also saw a reduction of MN to background
levels at the 28 weeks time point, but time course data was not collected. The ability of
genistein to reduce MN formation at late times was similar in the rat single dose and
mouse fractionated dose models.
The impact of genistein on the inflammatory response was also investigated.
Genistein also reduced the macrophage content in lung tissue assessed by MAC3 staining
by ~22% and the deposition of collagen by ~28% as assessed by Masson’s Trichrome
staining. However, protection against DNA damage and MN formation did not extend to
significant protection against increases in breathing rate or decreased severe morbidity.
Histology confirmed that animals that were sick in the 12-16 week time window had
developed severe pneumonitis, and portions of the lung were completely obliterated by
inflammatory infiltrate. Previous studies with genistein in our lab in rats monitored
breathing rate (Figure 3.1, Calveley, in preparation) and survival (Figure 3.2 Calveley, in
preparation) but did not examine histology except at 28 weeks PI. In rats following a
single dose of radiation genistein reduced breathing rates during pneumonitis, but this
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effect was lost during fibrosis as breathing rates increased again.

Genistein also

increased the median survival time, most of the treated rats survived during pneumonitis,
but later died during the fibrotic phase. Together these results show that Genistein is
having an effect on the inflammatory response, but this effect was not significant enough
to affect mortality. These results of previous work in rats are quite similar to those
observed in this study. Further studies using higher doses of genistein may show larger
protective effects. Studies of various doses of genistein following whole body irradiation
showed a range of responses, with protection increasing according to doses up to
400mg/kg without toxicity [145].

This supports the idea for future studies that an

increase in dose may be required to have complete protection against severe pneumonitis
and fibrosis causing lethality.
The timing of genistein doses is also important. Langan et al. [119] investigated
the effects of delivering doses for shorter time periods following irradiation, and for
longer sustained treatments. Langan et al. showed protective effects when given 1 or 2
weeks PI. Perhaps larger doses given for a shorter period of time following irradiation or
at critical time periods, during pneumonitis, would provide more protection to the lung.
However, other studies have shown that long term administration of protective agents
provided protection but short term administration did not [94, 122]. The best timing for
administration is still unclear. Other studies in our lab are investigating the effects of
~50mg/kg genistein delivered by implanted subcutaneous osmotic pumps for 12 weeks,
and may provide more insight into this matter.

A combination of agents, such as

genistein plus EUK-189 may also produce synergistic effects. Higher doses of genistein
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Figure 3-1: Survival data from previous experiments in rats, 18Gy Whole lung irradiation (Calveley, in
preparation). Rats fed the genistein diet survived better than rats fed the control diet during pneumonitis
but later succumbed to fibrosis.
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Figure 3-2: Breathing rate data from previous experiments in rats, 18Gy Whole lung irradiation (Calveley,
in preparation). Genistein provided protection against early increases in breathing rate during pneumonitis,
but this effect was lost later during fibrosis.
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may protect against pneumonitis while another agent may be given to protect against
fibrosis.
Whenever any protective agent is given in combination with radiation therapy
there is a concern that it may protect tumour as well. There is considerable debate as to
whether to give antioxidants during radiotherapy [184-190].

There is concern that

increasing the antioxidant capacity of cells, particularly tumor cells would lessen the
effect of radiation that kills tumor cells via oxidative damage. However, this study
showed that genistein did not impact upon tumor radiosensitivity in KHT tumors in vivo.
This effect should be examined in other tumor models to ensure that this effect was not
cell specific, and at higher doses of genistein. Several studies have also shown antimetastatic potential of anti-oxidants and genistein that would support their use during or
after radiation therapy. The importance of timing doses would be important if they were
as effective given after therapy as during then there would not be interaction directly with
tumor cell kill during radiation.

3.2 Future Directions
The current study provided great insight into the effects of genistein following
fractionated lung irradiation in mice. Genistein showed some protective effects against
MN formation and inflammation, but future studies should investigate higher doses to try
to provide complete protection and prevent lethality. The dose may be increased in the
diet or supplemented with osmotic pumps, or injections. The increased dose may only
need to be delivered during critical time periods, but the exact timing merits further
investigation. If genistein proves to be more effective in blocking pneumonitis and not
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fibrosis then perhaps a combination with agents such as EUK-189 may have synergistic
protective effects.
In this study tissue samples were taken at 4 week intervals that could be analyzed
for RNA expression of various inflammatory cytokines. However, in rats Calveley (in
preparation) did not see an effect of genistein using the same diet on cytokine expression
in tissue samples except for TNF-α.

If genistein did not impact upon cytokine

expression, high pro-inflammatory cytokine levels would still allow for perpetuation of
the inflammatory response. Likely a larger dose of genistein may be required to impact
upon cytokine levels as well as DNA damage.
Blood samples were also taken from the mice and are available to measure plasma
concentration of genistein to confirm the expected calculated dose, and possibly compare
with levels in rat plasma too. There may be differences in bioavailability of genistein
between rats and mice, and between different strains of mice.
There is a disconnect between the levels of MN damage observed and the
functional deficit and survival observed. The MN assay has been used previously to
assess regional damage in lung quadrants, and provided great insight into out-of-field
effects. In the current experiment there did not appear to be a correlation with the
reduced MN formation and DNA damage in genistein-treated animals and increased
survival. The MN assay may be reflective of ROS levels within the cell as opposed to
levels of ROS produced by inflammation outside the cell which may play a larger role in
the development of severe symptoms. Perhaps investigation of other assays of DNA or
cell damage such as 8-oxoguanine or lipid peroxidation assays may provide

79

measurements of oxidative damage that are more relevant to survival outcome than MN
formation.
This study focused on inflammatory macrophages present in the lung tissue.
Examining levels of macrophages and inflammatory mediators present in bronchiolar
lavage fluid (BALF) may also provide insight into inflammatory processes and timing of
expression following lung irradiation.
Genistein did not impact upon tumor response in KHT fibrosarcoma cells
irradiated in situ. This effect should be examined at higher doses as well, and in other
cell lines such as human lung carcinoma H460 to ensure that this effect is not cell type
specific before applying this agent to clinical use. It is important that any therapeutic
agent not interfere with the effectiveness of radiation killing of tumor cells.

3.3 Conclusion
Studies examining DNA damage, lung inflammation and protective agents are
necessary to better understand the mechanisms of radiation-induced lung damage.
Radiation pneumonitis and fibrosis are damaging side effects that limit the amount of
radiation that can be delivered to treat cancer of the lung and surrounding tissues. This
study examined the anti-oxidant and anti-inflammatory agent genistein to determine if
blocking oxidative damage and the inflammatory response can impact upon the
development of radiation pneumonitis and fibrosis.

A greater understanding of the

mechanisms leading to development of side effects is needed to successfully mitigate and
treat them.

Further work investigating the role of chronic oxidative stress and

inflammation following lung irradiation will contribute to the development of therapies in
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this field to allow larger doses of radiation to be delivered to improve treatment
outcomes.
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